Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (VRTX)
NASDAQ:VRTX
VRTX Stock Chart & Stats
$447.38
$0.48(0.12%)
At close: 4:00 PM EST
$447.38
$0.48(0.12%)
Day’s Range― - ―
52-Week Range$362.50 - $519.68
Previous CloseN/A
Volume295.43K
Average Volume (3M)1.33M
Market Cap
$115.75B
Enterprise Value$96.43B
Total Cash (Recent Filing)$6.29B
Total Debt (Recent Filing)$1.83B
Price to Earnings (P/E)32.2
Beta0.57
Next Earnings
Feb 04, 2026EPS Estimate
5.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.80
Shares Outstanding253,718,830
10 Day Avg. Volume1,267,020
30 Day Avg. Volume1,328,222
Financial Highlights & Ratios
PEG Ratio1.69
Price to Book (P/B)6.32
Price to Sales (P/S)9.41
P/FCF Ratio-131.21
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue8.23
Enterprise Value/Gross Profit9.53
Enterprise Value/Ebitda20.69
Forecast
1Y Price Target
$512.06Price Target Upside14.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pipeline ExpansionThe Outperform rating is supported by the fundamental analysis suggesting that the CF opportunity continues to be foundational for pipeline expansion and that there is room for share upside.
Prescription GrowthManagement noted that as of mid-October, Journavx had reached over 300,000 prescriptions, across both the retail and hospital settings.
Renal ProgramsVertex’s renal programs are emerging as the company’s next major growth driver, building on the success of its cystic fibrosis franchise.
Bears Say
Commercial ChallengesDespite the growth in the therapeutic landscape of IgAN, the slow penetration of currently approved drugs means Vertex might have some work to do at the commercial front.
Market CompetitionThe IgAN market is expected to be highly competitive, with Vertex's Pove potentially being the third entrant, which could limit market share.
Valuation ConcernsAt a premium valuation, Vertex shares currently trade at a P/E multiple of 20.5x 2026E consensus EPS vs. the mega-cap BioPharma peer average of 14.0x, leading to a Hold rating.
Vertex Pharmaceuticals News
VRTX FAQ
What was Vertex Pharmaceuticals’s price range in the past 12 months?
Vertex Pharmaceuticals lowest stock price was $362.50 and its highest was $519.68 in the past 12 months.
What is Vertex Pharmaceuticals’s market cap?
Vertex Pharmaceuticals’s market cap is $115.75B.
When is Vertex Pharmaceuticals’s upcoming earnings report date?
Vertex Pharmaceuticals’s upcoming earnings report date is Feb 04, 2026 which is in 46 days.
How were Vertex Pharmaceuticals’s earnings last quarter?
Vertex Pharmaceuticals released its earnings results on Nov 03, 2025. The company reported $4.8 earnings per share for the quarter, beating the consensus estimate of $4.573 by $0.227.
Is Vertex Pharmaceuticals overvalued?
According to Wall Street analysts Vertex Pharmaceuticals’s price is currently Undervalued.
Does Vertex Pharmaceuticals pay dividends?
Vertex Pharmaceuticals does not currently pay dividends.
What is Vertex Pharmaceuticals’s EPS estimate?
Vertex Pharmaceuticals’s EPS estimate is 5.12.
How many shares outstanding does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has 253,718,830 shares outstanding.
What happened to Vertex Pharmaceuticals’s price movement after its last earnings report?
Vertex Pharmaceuticals reported an EPS of $4.8 in its last earnings report, beating expectations of $4.573. Following the earnings report the stock price went up 0.101%.
Which hedge fund is a major shareholder of Vertex Pharmaceuticals?
Currently, no hedge funds are holding shares in VRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vertex Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$512.06 (14.46% Upside)
$512.06 (14.46% Upside)
Blogger Sentiment
Bullish
VRTX Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 281.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.7%
Last 30 Days ▲ 9.8%
Last 30 Days ▲ 9.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.02%
12-Months-Change
Fundamentals
Return on Equity
22.31%
Trailing 12-Months
Asset Growth
11.79%
Trailing 12-Months
Company Description
Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on the discovery, development, and commercialization of innovative medicines for serious diseases. The company primarily operates in the fields of cystic fibrosis (CF) and other serious diseases, leveraging its expertise in genetics and drug development to create transformative therapies. Vertex is best known for its portfolio of CF treatments, including Kalydeco, Orkambi, and Trikafta, which target the underlying causes of the disease rather than just its symptoms.
VRTX Company Deck
VRTX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with strong financial performance, significant revenue growth across multiple products, and promising pipeline advancements, particularly in the renal and CF segments. However, challenges remain with high gross to net impacts and some regulatory and development delays.View all VRTX earnings summariesVRTX Revenue Breakdown
92.91% TRIKAFTA/KAFTRIO
7.09% Other product revenues
VRTX Stock 12 Month Forecast
Average Price Target
$512.06
▲(14.46% Upside)
Technical Analysis
Ownership Overview
0.22% Insiders
37.00% Mutual Funds
32.83% Other Institutional Investors
2.25% Public Companies and Individual Investors